The ARHGAP1 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from the human HT29 colorectal adenocarcinoma line, featuring targeted disruption of the ARHGAP1 gene to create a loss-of-function model. This product provides a heterogeneous pool of edited cells that collectively harbor ARHGAP1 knockout alleles, enabling functional interrogation of this Rho GTPase-activating protein in a disease-relevant cellular context without clonal selection bias. The polyclonal format preserves a broad representation of editing events, making it suitable for pooled phenotypic screens and downstream analyses where population-level responses are desired.
The HT29 host cell line is a widely characterized human colorectal adenocarcinoma model isolated from a 44-year-old female patient. These epithelial cells are extensively employed in cancer biology, drug transport, and intestinal barrier function studies due to their reproducible growth characteristics and well-documented signaling networks. As a colon carcinoma line, HT29 retains key features of colorectal malignancy, including dysregulated proliferation and the capacity for epithelial-mesenchymal transition, rendering it an appropriate system for investigating molecular determinants of colorectal cancer progression and metastasis.
ARHGAP1 encodes a GTPase-activating protein that accelerates the intrinsic GTP hydrolysis of Rho family GTPases, notably RhoA, Rac1, and Cdc42, thereby terminating their active signaling states. This regulatory function positions ARHGAP1 as a critical node in actin cytoskeleton dynamics, cell adhesion, and migration. In wild-type HT29 cells, ARHGAP1 operates downstream of integrin beta1 and focal adhesion kinase (FAK) and upstream of effectors such as p21-activated kinase 1 (PAK1), LIM kinase (LIMK), and cofilin. Additionally, it interacts with adaptor proteins like paxillin and SH3 domain-containing partners, fine-tuning Rho-driven contractility and protrusion. CRISPR/Cas9-mediated disruption of ARHGAP1 removes this inhibitory constraint, leading to sustained Rho GTPase activation, enhanced actomyosin-based stress fiber assembly, and aberrant migratory behavior.
In the context of HT29 colorectal adenocarcinoma cells, ARHGAP1 knockout holds particular significance for dissecting the mechanistic underpinnings of colon carcinoma cell migration and invasion. Hyperactivation of RhoA, Rac1, and Cdc42 is implicated in metastatic dissemination, and this polyclonal knockout model recapitulates such dysregulation, offering a platform to examine how unrestrained Rho signaling alters cell-matrix adhesion, cytoskeletal remodeling, and collective cell movement. The HT29 background further supports studies of epithelial barrier integrity and drug penetration, enabling researchers to cross-correlate Rho-dependent morphological changes with functional outcomes in a therapeutically relevant setting.
This ARHGAP1 knockout product is well-suited for a range of advanced experimental applications, including quantitative wound healing and transwell migration assays to assess motility phenotypes, immunofluorescence microscopy of actin networks and focal adhesion complexes, and Rho GTPase activity pulldown assays to directly measure GTP-RhoA, Rac1, or Cdc42 levels. Complementary techniques such as RNA sequencing, western blotting for downstream targets like phosphorylated cofilin or PAK1, and proliferation assays further expand the toolkit for characterizing the knockout impact. These cells also serve as a model for epithelial-mesenchymal transition research and for evaluating anti-metastatic drug responses in colorectal cancer. For additional product details or technical inquiries, please contact Ascent Research.
